Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease

American Journal of Respiratory and Critical Care Medicine

Volumn 183, Issue 9, 2011, Pages 1187-1192

  Sin, Don D ^a,b   Miller, Bruce E ^c   Duvoix, Annelyse ^d   Man, S F Paul ^a,b   Zhang, Xuekui ^a   Silverman, Edwin K ^e   Connett, John E ^f   Anthonisen, Nicholas A ^g   Wise, Robert A ^h   Tashkin, Donald ⁱ   Celli, Bartolome R ^e   Edwards, Lisa D ^c   Locantore, Nicholas ^c   MacNee, William ^j   Tal Singer, Ruth ^c   Lomas, David A ^d  

^a The James Hogg iCAPTURE Centre for Cardiovascular and Pulmonary Research   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c GLAXOSMITHKLINE   (United States)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

^g UNIVERSITY OF MANITOBA   (Canada)

^h JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j UNIVERSITY OF EDINBURGH   (United Kingdom)

more..

Author keywords

Biomarker; Chemokine; Chronic obstructive pulmonary disease; PARC CCL 18

Indexed keywords

CC CHEMOKINE LIGAND 18; CHEMOKINE; PREDNISOLONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HOSPITALIZATION; HUMAN; INTERVENTION STUDY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SMOKING;

ANTI-INFLAMMATORY AGENTS; BIOLOGICAL MARKERS; CHEMOKINES, CC; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HOSPITALIZATION; HUMANS; KAPLAN-MEIER ESTIMATE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREDNISOLONE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SMOKING;

EID: 79955513658     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201008-1220OC     Document Type: Article

References (25)

1. Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AM, Sullivan SD, Lee TA, Weiss KB, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007;370:741-750.
2. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet 1997;349:1498-1504.
3. Katz R. Biomarkers and surrogate markers: an FDA perspective. NeuroRx 2004;1:189-195.
4. Gunther C, Bello-Fernandez C, Kopp T, Kund J, Carballido-Perrig N, Hinteregger S, Fassl S, Schwarzler C, Lametschwandtner G, Stingl G, et al. CCL18 is expressed in atopic dermatitis and mediates skin homing of human memory T cells. J Immunol 2005;174:1723-1728.
5. Kraaijeveld AO, de Jager SC, de Jager WJ, Prakken BJ, McColl SR, Haspels I, Putter H, van Berkel TJ, Nagelkerken L, Jukema JW, et al. CC chemokine ligand-5 (CCL5/RANTES) and CC chemokine ligand- 18 (CCL18/PARC) are specific markers of refractory unstable angina pectoris and are transiently raised during severe ischemic symptoms. Circulation 2007;116:1931-1941.
6. Prasse A, Pechkovsky DV, Toews GB, Schafer M, Eggeling S, Ludwig C, Germann M, Kollert F, Zissel G, Muller-Quernheim J. CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis. Arthritis Rheum 2007;56:1685-1693.
7. Struyf S, Schutyser E, Gouwy M, Gijsbers K, Proost P, Benoit Y, Opdenakker G, Van Damme J, Laureys G. PARC/CCL18 is a plasma CC chemokine with increased levels in childhood acute lymphoblastic leukemia. Am J Pathol 2003;163:2065-2075.
8. Prasse A, Probst C, Bargagli E, Zissel G, Toews GB, Flaherty KR, Olschewski M, Rottoli P, Muller-Quernheim J. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009;179:717-723.
9. Pinto-Plata V, Toso J, Lee K, Park D, Bilello J, Mullerova H, De Souza MM, Vessey R, Celli B. Profiling serum biomarkers in patients with COPD: associations with clinical parameters. Thorax 2007;62:595-601.
10. Hurst JR, Donaldson GC, Perera WR, Wilkinson TM, Bilello JA, Hagan GW, Vessey RS, Wedzicha JA. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;174:867-874.
11. Sin DD, Man SF, Connett JE, Anthonisen N, Wise R, Tashkin DP, Celli BR, Tal-Singer R, Edwards L, Locantore N, et al. Pulmonary and activation-regulated chemokine (PARC): new lung-specific blood biomarker for COPD? [abstract]. Am J Respir Crit Care Med 2009;179:A3763.
12. Lomas DA, Silverman EK, Edwards LD, Miller BE, Coxson HO, Tal-Singer R. Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort. Thorax 2008;63:1058-1063.
13. Man SF, Xing L, Connett JE, Anthonisen NR, Wise RA, Tashkin DP, Zhang X, Vessey R, Walker TG, Celli BR, et al. Circulating fibronectin to C-reactive protein ratio and mortality: a biomarker in COPD? Eur Respir J 2008;32:1451-1457.
14. Lomas DA, Silverman EK, Edwards LD, Locantore NW, Miller BE, Horstman DH, Tal-Singer R. Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. Eur Respir J 2009;34:95-102.
15. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005;142:233-239.
16. Vestbo J, Anderson W, Coxson HO, Crim C, Dawber F, Edwards L, Hagan G, Knobil K, Lomas DA, MacNee W, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J 2008;31:869-873.
17. O'Connor G, Sparrow D, Taylor D, Segal M, Weiss S. Analysis of dose- response curves to methacholine: an approach suitable for population studies. Am Rev Respir Dis 1987;136:1412-1417.
18. Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, Brusasco V, Burge PS, Calverley PM, Celli BR, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008;31:416-469.
19. Man SF, Xuekui Z, Vessey R, Walker T, Lee K, Park D, Sin DD. The effects of inhaled and oral corticosteroids on serum inflammatory biomarkers in COPD: an exploratory study. Ther Adv Respir Dis 2009;3:73-80.
20. Hieshima K, Imai T, Baba M, Shoudai K, Ishizuka K, Nakagawa T, Tsuruta J, Takeya M, Sakaki Y, Takatsuki K, et al. A novel human CC chemokine PARC that is most homologous to macrophage-inflammatory protein-1α/LD78α and chemotactic for T lymphocytes, but not for monocytes. J Immunol 1997;159:1140-1149.
21. Kodelja V, Muller C, Politz O, Hakij N, Orfanos CE, Goerdt S. Alternative macrophage activation-associated CC-chemokine-1, a novel structural homologue of macrophage inflammatory protein-1α with a Th2-associated expression pattern. J Immunol 1998;160:1411-1418.
22. Auer J, Blass M, Schulze-Koops H, Russwurm S, Nagel T, Kalden JR, Rollinghoff M, Beuscher HU. Expression and regulation of CCL18 in synovial fluid neutrophils of patients with rheumatoid arthritis. Arthritis Res Ther 2007;9:R94.
23. Adema GJ, Hartgers F, Verstraten R, de Vries E, Marland G, Menon S, Foster J, Xu Y, Nooyen P, McClanahan T, et al. A dendritic-cell- derived C-C chemokine that preferentially attracts naive T cells. Nature 1997;387:713-717.
24. Atamas SP, Luzina IG, Choi J, Tsymbalyuk N, Carbonetti NH, Singh IS, Trojanowska M, Jimenez SA, White B. Pulmonary and activation-regulated chemokine stimulates collagen production in lung fibroblasts. Am J Respir Cell Mol Biol 2003;29:743-749.
25. Kollert F, Probst C, Muller-Quernheim J, Zissel G, Prasse A. CCL18 production is decreased in alveolar macrophages from cigarette smokers. Inflammation 2009;32:163-168.